Univariate Survival Analysis by the IPI Score, Factors Used to Construct the IPI, B Symptoms, s-CD44 Level, WF Grade, and Gender
Factor . | N . | 5-yr Survival (%) . | P Value . |
---|---|---|---|
IPI score | |||
0 | 30 | 90 | <.0001 |
1 | 62 | 66 | |
≥2 | 91 | 33 | |
s-LDH | |||
≤450 U/L | 129 | 64 | <.0001 |
>450 U/L | 55 | 27 | |
WHO performance status | |||
0 | 103 | 70 | <.0001 |
1 | 59 | 46 | |
2-4 | 32 | 12 | |
Stage | |||
I | 65 | 69 | .0001 |
II | 50 | 58 | |
III | 32 | 40 | |
IV | 45 | 33 | |
Age | |||
≤60 yr | 104 | 62 | .0002 |
>60 yr | 90 | 41 | |
S-CD44, highest tertile | |||
≤514 ng/mL | 129 | 62 | .0005 |
>514 ng/mL | 65 | 38 | |
No. of extranodal sites | |||
0-1 | 172 | 56 | .001 |
>1 | 20 | 25 | |
B symptoms | |||
No | 155 | 58 | .002 |
Yes | 38 | 32 | |
S-CD44, median | |||
≤440 ng/mL | 97 | 62 | .007 |
>440 ng/mL | 97 | 44 | |
WF grade | |||
Low | 48 | 67 | .02 |
Intermediate | 90 | 55 | |
High | 48 | 38 | |
Gender | |||
Male | 88 | 56 | .37 |
Female | 106 | 51 |
Factor . | N . | 5-yr Survival (%) . | P Value . |
---|---|---|---|
IPI score | |||
0 | 30 | 90 | <.0001 |
1 | 62 | 66 | |
≥2 | 91 | 33 | |
s-LDH | |||
≤450 U/L | 129 | 64 | <.0001 |
>450 U/L | 55 | 27 | |
WHO performance status | |||
0 | 103 | 70 | <.0001 |
1 | 59 | 46 | |
2-4 | 32 | 12 | |
Stage | |||
I | 65 | 69 | .0001 |
II | 50 | 58 | |
III | 32 | 40 | |
IV | 45 | 33 | |
Age | |||
≤60 yr | 104 | 62 | .0002 |
>60 yr | 90 | 41 | |
S-CD44, highest tertile | |||
≤514 ng/mL | 129 | 62 | .0005 |
>514 ng/mL | 65 | 38 | |
No. of extranodal sites | |||
0-1 | 172 | 56 | .001 |
>1 | 20 | 25 | |
B symptoms | |||
No | 155 | 58 | .002 |
Yes | 38 | 32 | |
S-CD44, median | |||
≤440 ng/mL | 97 | 62 | .007 |
>440 ng/mL | 97 | 44 | |
WF grade | |||
Low | 48 | 67 | .02 |
Intermediate | 90 | 55 | |
High | 48 | 38 | |
Gender | |||
Male | 88 | 56 | .37 |
Female | 106 | 51 |